Skip to main content
. 2024 Mar 4;71:103105. doi: 10.1016/j.redox.2024.103105

Fig. 8.

Fig. 8

Illustrates the potential uses of dietary small molecules nanoformulations in AD. Dietary small molecules lower BBB permeability, poor solubility, and low bioavailability, they have failed to reduce disease progression and treat AD. The development of dietary small molecules-loaded nanocarrier systems can reduce these barriers while improving neuroprotective benefits. BBB: blood brain barrier.